Principia Biopharma to Present at the 2020 Bank of America Health Care Conference
May 05, 2020 16:05 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results
March 10, 2020 16:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
Principia to Present at 9th Annual SVB Leerink Global Healthcare Conference
February 19, 2020 08:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
Principia Announces Expansion of its BTK Franchise with PRN473 Topical
January 09, 2020 08:01 ET
|
Principia Biopharma Inc.
Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE...
Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases
January 07, 2020 08:01 ET
|
Principia Biopharma Inc.
Company’s lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE...
Principia Updates PRN1008 Pemphigus Clinical Program
December 30, 2019 08:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
December 07, 2019 10:00 ET
|
Principia Biopharma Inc.
ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases,...
Principia to Present at the Stifel Healthcare Conference 2019
November 13, 2019 08:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
Principia Biopharma Reports Third Quarter Financial Results
November 05, 2019 16:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
Principia Announces Pricing of Public Offering of Common Stock
October 15, 2019 22:24 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...